Evidence map›Paper›PMID 41068343›Full record

ArticleScientific reports2025

Comprehensive analysis of the tumor targeting efficiency of functionalized nanoparticles in an immunocompetent environment.

Nolan Jackson, Nasry Bouzeineddine, Daniel Cecchi, Safara Holder, Katrina Gee, Wayne Beckham, Sameh Basta, Sunil Krishnan, Devika B Chithrani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. How Key in vivo Models Can Advance Anticancer Nanotherapeutics.International journal of nanomedicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nolan JacksonDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.
Nasry BouzeineddineDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Daniel CecchiDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.
Safara HolderDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Katrina GeeDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Wayne BeckhamDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.
Sameh BastaDepartment of Biomedical and Molecular Sciences, Queen's University, Kingston, ON, Canada.
Sunil KrishnanVivian L. Smith Department of Neurosurgery, The University of Texas Health Science Center, Houston, TX, USA.
Devika B ChithraniDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada. devikac@uvic.ca.

Funding

Rational translation of gold nanoparticle mediated radiosensitization tothe clinicR01CA257241 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI Sang Hyun Cho, Sunil Krishnan · 2021 to 2026
$3.1M
CIHR CIHR PJT-399878NanoMedicines Innovation Network 2021-RES SI-05Natural Sciences and Engineering Research Council of Canada RGPIN-2017-04501NCI NIH HHS R01 CA257241NIH HHS R01CA257241
6 · The paper itself

Abstract

The success of nanoparticle-based cancer therapeutics relies on their efficient tumor uptake and retention. Given this, improving nanoparticle localization in tumors is paramount to maximize their therapeutic potential. A common approach to achieve this is to functionalize nanoparticles with active targeting moieties that bind to specific tumor-associated receptors. Among these, arginine-glycine-aspartic acid (RGD) peptides have shown a potential to promote tumor accumulation by targeting the α

Indexed as

Metal NanoparticlesNeoplasmsOligopeptidesAnimalsCell Line, TumorFemaleGoldHumansImmunocompetenceIntegrin alphaVbeta3MiceNanoparticlesPolyethylene Glycolsarginyl-glycyl-aspartic acidGoldIntegrin alphaVbeta3OligopeptidesPolyethylene Glycols

Identifiers

PMID41068343
PMCPMC12511637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.